We are live on ! Find out more
VPHM

VIROPHARMA INC
VPHM

Delisted

VPHM was delisted on the 23rd of January, 2014.

172 hedge funds and large institutions have $3.29B invested in VIROPHARMA INC in 2013 Q4 according to their latest regulatory filings, with 52 funds opening new positions, 47 increasing their positions, 61 reducing their positions, and 69 closing their positions.

New
Increased
Maintained
Reduced
Closed

175% more funds holding in top 10

Funds holding in top 10: 411 (+7)

14% more capital invested

Capital invested by funds: $2.87B → $3.29B (+$416M)

10% less funds holding

Funds holding: 191172 (-19)

23% less repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 61

25% less first-time investments, than exits

New positions opened: 52 | Existing positions closed: 69

57% less call options, than puts

Call options by funds: $67.1M | Put options by funds: $155M

Holders
172
Holders Change
-19
Holders Change %
-9.95%
% of All Funds
4.99%
Holding in Top 10
11
Holding in Top 10 Change
+7
Holding in Top 10 Change %
+175%
% of All Funds
0.32%
New
52
Increased
47
Reduced
61
Closed
69
Calls
$67.1M
Puts
$155M
Net Calls
-$87.5M
Net Calls Change
-$82.9M
Name Holding Trade Value Shares
Change
Change in
Stake
SG Americas Securities
151
SG Americas Securities
New York
$157K -$423K -9,466 -75%
Creative Planning
152
Creative Planning
Kansas
$140K
Bank of Montreal
153
Bank of Montreal
Ontario, Canada
$138K -$44.7K -1,000 -27%
Wells Fargo
154
Wells Fargo
California
$136K -$5.8M -129,744 -98%
Teacher Retirement System of Texas
155
Teacher Retirement System of Texas
Texas
$122K -$259K -5,781 -70%
WG
156
Welch Group
Alabama
$112K -$100K -2,243 -50%
BJ
157
BlackRock Japan
Japan
$112K -$5.77K -129 -5%
BlackRock
158
BlackRock
New York
$107K -$1.7K -38 -2%
SEC
159
Seven Eight Capital
New York
$85K +$76K +1,700 New
TFA
160
Transamerica Financial Advisors
Florida
$50K
TRCT
161
Tower Research Capital (TRC)
New York
$36K -$150K -3,363 -82%
Fifth Third Bancorp
162
Fifth Third Bancorp
Ohio
$30K -$58.4K -1,307 -69%
First Manhattan
163
First Manhattan
New York
$24K
US Bancorp
164
US Bancorp
Minnesota
$14K -$55K -1,231 -82%
CCM
165
Credo Capital Management
Maryland
$14K -$19.1K -427 -61%
MFS
166
MSI Financial Services
Massachusetts
$10K
LTFS
167
Ladenburg Thalmann Financial Services
Florida
$9K
PNC Financial Services Group
168
PNC Financial Services Group
Pennsylvania
$5K -$675K -15,099 -99%
Manulife (Manufacturers Life Insurance)
169
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$2.47K -$17.7K -396 -0.8%
PIA
170
Piedmont Investment Advisors
North Carolina
$1.05K +$939 +21 New
KCPG
171
Kavar Capital Partners Group
Kansas
$1K +$1.43K +32 New
BBA
172
Baker Bros. Advisors
New York
-$220M -5,592,239 Closed
PI
173
Putnam Investments
Massachusetts
-$189M -4,813,580 Closed
PC
174
PointState Capital
New York
-$87M -2,217,200 Closed
EAM
175
Eagle Asset Management
Florida
-$72.4M -1,849,580 Closed

VPHM Hedge Fund Activity: Q4 2013 in Review

172 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in VIROPHARMA INC (VPHM) for Q4 2013, worth a combined $3.29B — up 14% from $2.87B a quarter earlier.

Sellers outnumbered buyers: 69 funds closed out of VPHM and 52 opened new positions — a net loss of 17 holders — while 61 trimmed existing stakes and 47 added.

The largest buyer was Oxford Asset Management, opening a new position worth an estimated $137M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $220M sold.

  • 172 institutional investors held VIROPHARMA INC (VPHM) as of Q4 2013, down from 191 in Q3 2013.
  • Funds reported $3.29B of VIROPHARMA INC stock for Q4 2013, up 14% quarter-over-quarter.
  • 52 funds opened new VIROPHARMA INC positions in Q4 2013 and 69 closed out, a net change of -17 holders.
  • The largest VIROPHARMA INC buyer in Q4 2013 was Oxford Asset Management, an estimated $137M added.
  • The largest VIROPHARMA INC seller in Q4 2013 was Baker Bros. Advisors, an estimated $220M sold.

Based on aggregated 13F filings for Q4 2013.